- New Mexico AG Raúl Torrez announced settlements with Sanofi-Aventis U.S. LLC and Novo Nordisk Inc. to resolve allegations that the pharmaceutical companies’ pricing policies resulted in underinsured and uninsured patients paying higher prices for insulin.
- Under the terms of the agreements, Sanofi-Aventis and Novo Nordisk will cap the price of insulin at $35 per month for uninsured New Mexico residents for the next five years; provide free insulin to the highest-need consumers below the poverty line; clearly disclose insulin affordability programs to consumers; and provide bilingual customer service, among other things.
- We have previously covered other AGs reaching similar insulin price cap agreements with pharmaceutical companies, including Maine AG Aaron Frey, Minnesota AG Keith Ellison, and New York AG Letitia James.